Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
Market Challenges | Waters Corporation faces headwinds in Industrial and Applied & General segments, with significant declines in quarterly instrument revenues impacting overall performance. |
Pharma Sector Strength | Explore Waters' robust position in the Pharmaceutical segment, offering potential for growth and stability amidst broader market uncertainties. |
Recovery Prospects | Delve into management's optimistic outlook for a strong second-half recovery, particularly in Q4, despite conservative guidance and market skepticism. |
Analyst Perspectives | Barclays Capital sets price targets of $295-$300, reflecting cautious optimism amid Waters' efforts to navigate challenging market conditions. |
Metrics to compare | WAT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWATPeersSector | |
---|---|---|---|---|
P/E Ratio | 36.6x | 26.2x | −0.6x | |
PEG Ratio | −7.73 | 0.10 | 0.00 | |
Price/Book | 14.2x | 4.1x | 2.6x | |
Price / LTM Sales | 7.8x | 2.4x | 3.2x | |
Upside (Analyst Target) | −3.5% | 25.9% | 44.6% | |
Fair Value Upside | Unlock | −0.9% | 7.3% | Unlock |